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CASE REPORT Open Access
Conversion of autoimmune hypothyroidism to
hyperthyroidism
Saira Furqan*, Naeem-ul Haque and Najmul Islam
Abstract
Background: Graves’ disease and Hashimoto’s thyroiditis are the two autoimmune spectrum of thyroid disease.
Cases of conversion from hyperthyroidism to hypothyroidism have been reported but conversion from
hypothyroidism to hyperthyroidism is very rare. Although such cases have been reported rarely in the past we are
now seeing such conversions from hypothyroidism to hyperthyroidism more frequently in clinical practice.
Case presentation: We are reporting three cases of middle aged Asian females who presented with classical
symptoms of hypothyroidism and the investigations showed elevated thyroid stimulating hormone with positive
thyroid antibodies. Diagnosis of autoimmune hypothyroidism was made and thyroxine replacement therapy was
initiated. Patients became asymptomatic with normalization of thyroid stimulating hormone level. After few years
they developed symptoms of hyperthyroidism with suppressed thyroid stimulating hormone level. Over
replacement of thyroxine was considered and the dose of thyroxine was decreased, but they remain symptomatic.
After gradual decrease in the dose of thyroxine it was stopped finally. Even after few months of stopping thyroxine,
the symptoms of hyperthyroidism did not improve and the biochemical and imaging modalities confirmed that the
patients have developed hyperthyroidism. Anti-thyroid treatment was then started and the patients became
symptom free.
Conclusion: High index of suspicion should be there for possible conversion of hypothyroidism to hyperthyroidism
if a patient with primary hypothyroidism develops persistent symptoms of hyperthyroidism. Otherwise it can be
missed easily considering it as an over replacement with thyroid hormone.
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Background
Autoimmune thyroid disease is one of the commonest
autoimmune diseases, affecting 2-4% of women and 1% of
men [1-3]. Grave’s disease and Hashimoto’s thyroiditis are
the two autoimmune spectrum of thyroid disease. They
have a complex etiology with poorly understood pathogen-
esis. The pathogenesis is influenced by certain environmen-
tal, hormonal and genetic factors. In both autoimmune
hypothyroidism and Grave’s disease, genetic factors play a
major role [4]. Cases of conversion from hyperthyroidism
to hypothyroidism have been reported [5] but conversion
from hypothyroidism to hyperthyroidism is thought to be
very rare, although reported [6]. We are reporting three
cases of autoimmune hypothyroidism that have converted
to hyperthyroidism requiring anti-thyroid treatment.
Cases presentation
Case 1
A 36 years old female presented with a 3 months history
of easy fatigability, cold intolerance, polymenorrhagia,
constipation and weight gain in the beginning of year
2005. On examination she had bradycardia and dry skin.
The thyroid gland was palpable, non-tender mostly diffuse
but some nodular feeling at upper pole of left lobe. Clin-
ical suspicion of primary hypothyroidism was made and it
was confirmed by TSH value of greater than 50 uIU/ml
with FT4 of less than 0.30 ng/dl and positive thyroid anti-
bodies. Thyroxine was started at a dose of 100 mcg/day.
Gradually the requirement of thyroxine decreased and by
the end of 2005 onwards she maintained her TSH within
normal range on 50 mcg/day of thyroxine. In the begin-
ning of 2008 the dose was further reduced to 25 mcg/day
but again towards the end of 2009 thyroxine dose was in-
creased to 50 mcg/day because of slightly increased TSH
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of 8.86 uIU/ml. Slightly more than a year later in the be-
ginning of 2011, she presented with weight loss of 3 kg
with a feeling of anxiety and associated tremors of
hands. TSH at this time was less than 0.005 uIU/ml with
a FT4 of 2.4 ng/dl, confirming the state of thyrotoxi-
cosis. Thyroxine was stopped and patient was observed
intermittently over a period of 6 months. She remained
clinically and biochemically hyperthyroid with a repeat
TSH of <0.005 uIU/ml and an FT4 of 2.66 ng/dl. Thy-
roid scintigraphy with technetium 99 was done and it
showed an increased homogenous tracer uptake. Finally
she was started on Neomercazole in mid of 2011and re-
mains on it till to date.
Case 2
46 years old female, mother of 3 children diagnosed as
having primary hypothyroidism on the basis of clinical
symptoms of easy fatigability, weight gain and increase
sleep and a serum TSH level of >75 uIU/ml, FT4:
0.25 ng/dl and strongly positive thyroid antibodies in
December 2002. Thyroxine 50 mcg/day was started
which she continued. After 2 years she presented to us
with complain of weight loss. Her serum TSH level was
0.035 uIU/ml and a T4: 7.84 ng/dl so thyroxine was
stopped. She came for follow up after 5 months with
serum TSH: 0.010 uIU/ml off thyroxine. After another
6 months her serum TSH remained suppressed with a
value of 0.018 uIU/ml and an FT4 of 1.18 ng/dl and she
remained off thyroxine. After further 2 years her TSH was
0.837 uIU/ml, FT4 0.922 ng/dl and FT3 3.06. And after
1 year she presented with a TSH level of <0.005 uIU/ml,
raised FT4 and positive thyroid microsomal antibodies (1:
1600). Techniteum 99 thyroid scan showed diffusely in-
creased homogenous tracer uptake. Neomercazole was
started at the dose of 5 mg/day which was gradually in-
creased to 10 mg/day. She followed up after 4 months
with TSH: 0.01 uIU/ml, T4: 5.84 ng/dl, T3: 1.99 ng/dl.
Neomercazole was continued. Then she came for follow
up after 1 year, at this time she was clinically euthyroid
but biochemically hypothyroid with serum TSH: 14.89
uIU/ml, FT4:0.65 ng/dl. Neomercazole was stopped and
advised to repeat TFT’s after 8 weeks. She came after
4 months with TSH: 3.98 uIU/ml, so no treatment was ad-
vised. After a period of 1 year she again came with com-
plains of weight loss and palpitations. At this time her
TSH: < 0.005 uIU/ml, FT4: 2.25 ng/dl. Neomercazole was
restarted and Radioactive iodine 131 ablation planned.
Case 3
A 43 year old obese female, married, mother of 4 children
was diagnosed as having hypothyroidism in the beginning
of year 2011 when she felt lethargic and her TSH level was
raised to 72 uIU/ml. She was started on thyroxine 150
mcg/day which was later on decreased to 100 mcg when
her TSH level was suppressed to 0.5 uIU/ml after 1 month.
After further 4 weeks her serum TSH came out to be fur-
ther suppressed at <0.005 uIU/ml so thyroxine was
stopped. The patient came for follow up after 8 weeks with
serum TSH of 0.2 uIU/ml and T4 of 16.20 ng/dl (4.5-
11.3). She then lost to follow up and returned in Septem-
ber 2011 with Thyroid function test showing serum TSH
of <0.005 uIU/ml and FT4: 2.36 ng/dl. Thyroid antibodies
were strongly positive. At this time she also had com-
plained of palpitations, increased appetite, increased bowel
movements, decreased sleep and tremors of hands. On
examination she had no goiter and eye signs but had fine
tremors of hands. She was advised to start carbimazole.
Discussion
In this case series, we have discussed 3 patients who devel-
oped hyperthyroidism after few months or years of estab-
lished hypothyroidism. Initially they were proven to have
autoimmune hypothyroidism on the basis of clinical and
biochemical parameters, with multiple elevated levels of
serum TSH and strongly positive thyroid antibodies. They
remained euthyroid on thyroxine therapy for quite a while.
Afterwards they developed clinical and biochemical hyper-
thyroidism, for which thyroxine was gradually decreased
and finally stopped, but they remained hyperthyroid even
after months of stopping thyroxine. Finally they needed
anti-thyroid treatment.
Primary Hypothyroidism once established has been
considered as a stable or gradually progressing disease
for which lifelong replacement therapy is needed but
very occasionally the condition might reverse. Review of
literature showed that so far 37 cases has been reported
where hypothyroidism later on converted to hyperthyroid-
ism. It was first reported in 1959 by Joplin and Fraser [7].
In 1960 Doniach et al. [8] reported the same. Gavras and
Thomson [9] documented two cases that developed
hyperthyroidism while they were taking thyroxine therapy
for hypothyroidism. Others have also reported the same
[10-32]. Takasu et al. [6] published a case series of 8 pa-
tients who were initially hypothyroid but later on converted
to hyperthyroidism. Bando et al. and Ruchala et al. reports
cases of hyperthyroidism following hypothyroidism in cases
of thyroid hemiagenesis [33,34].
Why a patient with established hypothyroidism later on
converts to hyperthyroidism is not well understood. Several
mechanisms have been postulated behind this conversion.
One important mechanism hypothesized is the presence of
different autoantibodies that includes thyroid stimulating
antibodies, thyroid stimulation blocking antibodies and the
response of thyroid gland to these antibodies [35].
The transition from TSH blocking antibodies to thyroid
stimulation antibodies may be the cause of hyperthyroid-
ism. Some patients actually have both antibodies specific to
Hashimoto’s and Graves’ disease, which puts the thyroid
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into a push-pull situation, where it cycles up and down
through hypothyroidism and hyperthyroidism. Other pos-
sible explanation for this transition from hypothyroidism to
hyperthyroidism is that the auto-immune tissue damage,
initially severe enough to cause thyroid hypofunction,
recovered sufficiently to allow subsequent stimulation by
TSAb [36]. Unfortunately these antibody testing haves not
been done in our patients due to non-availability of these
tests at our set up.
Although there are anecdotal reports that showed that
patients diagnosed with hypothyroidism and taking treat-
ment for it, developed hyperthyroidism later on. It was
thought to be a rare phenomenon but we have identified 3
patients in a short period of time so it seems that it is be-
coming a common occurrence and no more a rare prob-
lem. So the index of suspicion should be high.
Conclusion
These cases demonstrate that diagnosis of primary
hypothyroidism does not necessarily means lifelong re-
placement of thyroid hormone.
High index of suspicion should be there for a possible
conversion of hypothyroidism to hyperthyroidism if a pa-
tient with primary hypothyroidism develops persistent
symptoms of hyperthyroidism. Otherwise it can be missed
easily considering it as an over replacement with thyroid
hormone.
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